Gilmore ONeill - Sarepta Therapeutics Senior Vice President Chief Medical Officer
| SRPT Stock | USD 129.62 0.85 0.66% |
President
Mr. Gilmore ONeill is Executive Vice President, RD and Chief Medical Officer of the Company. Dr. ONeill has served as our Chief Medical Officer from June 2018. Prior to this appointment, Dr. ONeill served as the Senior Vice President, Late Stage Clinical Development of Biogen Inc. from November 2016 to June 2018. At Biogen, Dr. ONeill also served as Senior Vice President, Drug Innovation Units from October 2015 to November 2016. From June 2014 to October 2015, Dr. ONeill served as Vice President, MS Franchise Head, Multiple Sclerosis RD at Biogen. Prior to this role, Dr. ONeill served in numerous roles at Biogen since he joined the company in April 2003, including Vice president, Global Neurology Clinical Development, Vice president, Global Late Stage Clinical Development and Vice president, Experimental Neurology . Dr. ONeill is licensed to practice medicine in the state of Massachusetts. He is a member of the American Academy of Neurology and a boardcertified neurologist . Dr. ONeill is formerly Chief Resident in Neurology at the Massachusetts General Hospital and served, until recently, as a Clinical Instructor in Neurology at Harvard Medical School. From 1997 to 2015, Dr. ONeill served as a clinical instructor in neurology at Harvard Medical School. He also serves on the board of directors of the Massachusetts Biotechnology Council . Dr. ONeill has maintained his clinical appointment at the MGH with a subspecialty interest in neuromuscular diseases and inherited leukodystrophies since 2018.
| Age | 53 |
| Tenure | 6 years |
| Address | 215 First Street, Cambridge, MA, United States, 02142 |
| Phone | 617 274 4000 |
| Web | https://www.sarepta.com |
Sarepta Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.0524) % which means that it has lost $0.0524 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.8615) %, meaning that it created substantial loss on money invested by shareholders. Sarepta Therapeutics' management efficiency ratios could be used to measure how well Sarepta Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.17 in 2024. Return On Capital Employed is likely to drop to -0.11 in 2024. At this time, Sarepta Therapeutics' Total Current Liabilities is comparatively stable compared to the past year. Liabilities And Stockholders Equity is likely to gain to about 3.4 B in 2024, whereas Non Current Liabilities Other is likely to drop slightly above 39 M in 2024.Similar Executives
| Found 9 records | PRESIDENT Age | ||
| Wendy Rieder | Madrigal Pharmaceuticals | 46 | |
| Marc Schneebaum | Madrigal Pharmaceuticals | 64 | |
| Rebecca Taub | Madrigal Pharmaceuticals | 66 | |
| Suma Krishnan | Krystal Biotech | 59 | |
| Erin MD | Terns Pharmaceuticals | 53 | |
| Gregory Zante | Viking Therapeutics | 53 | |
| Amy Broidrick | Viking Therapeutics | N/A | |
| Catherine Kelleher | Viking Therapeutics | N/A | |
| Greg Zante | Viking Therapeutics | N/A | |
Management Performance
| Return On Equity | -0.86 | ||||
| Return On Asset | -0.0524 |
Sarepta Therapeutics Leadership Team
Elected by the shareholders, the Sarepta Therapeutics' board of directors comprises two types of representatives: Sarepta Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Sarepta. The board's role is to monitor Sarepta Therapeutics' management team and ensure that shareholders' interests are well served. Sarepta Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Sarepta Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Edward Kaye, Senior Vice President Chief Medical Officer | ||
| Alexander Cumbo, Vice President Head of Commercial | ||
| William Ciambrone, Ex Operations | ||
| Dallan Murray, Executive Officer | ||
| Hans Wigzell, Independent Director | ||
| Michael Bonney, Director | ||
| Sandesh Mahatme, CFO, Chief Accounting Officer and Sr. VP | ||
| Ryan JD, General VP | ||
| Jayant Aphale, Senior Vice President - Technical Operations | ||
| Mary Gray, Director | ||
| Douglas Esq, CEO President | ||
| Anthony Chase, Independent Director | ||
| Douglas Ingram, President CEO | ||
| Gilmore ONeill, Senior Vice President Chief Medical Officer | ||
| JeanPaul Kress, Director | ||
| Joan Wood, Vice President - Human Resources | ||
| Alison Nasisi, Executive Officer | ||
| Bilal Arif, Executive Officer | ||
| Ryan Brown, Gen VP | ||
| Richard Barry, Independent Director | ||
| Gil Price, Independent Director | ||
| Catherine StehmanBreen, Senior Vice President Chief Medical Officer | ||
| David Howton, Sr. VP, General Counsel and Corporate Secretary | ||
| Mary Jenkins, Sr Relations | ||
| Ian Estepan, Executive CFO | ||
| Guriqbal Basi, Senior Vice President Chief Scientific Officer | ||
| Will Tilton, Head VP | ||
| William Goolsbee, Non-Executive Independent Chairman of the Board | ||
| Louise RodinoKlapac, Chief VP | ||
| Claude Nicaise, Independent Director | ||
| Kathleen Behrens, Independent Director | ||
| Diane Berry, Executive Officer | ||
| Erin Cox, IR Contact | ||
| Shamim Ruff, Senior Vice President - Regulatory Affairs and Quality | ||
| Francesca Nolan, Executive Communications |
Sarepta Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Sarepta Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.86 | ||||
| Return On Asset | -0.0524 | ||||
| Profit Margin | (0.43) % | ||||
| Operating Margin | 0.06 % | ||||
| Current Valuation | 11.81 B | ||||
| Shares Outstanding | 94.51 M | ||||
| Shares Owned By Insiders | 4.39 % | ||||
| Shares Owned By Institutions | 86.90 % | ||||
| Number Of Shares Shorted | 4.87 M | ||||
| Price To Earning | (20.43) X |
Currently Active Assets on Macroaxis
When determining whether Sarepta Therapeutics is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Sarepta Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Sarepta Therapeutics Stock. Highlighted below are key reports to facilitate an investment decision about Sarepta Therapeutics Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sarepta Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey. For more information on how to buy Sarepta Stock please use our How to Invest in Sarepta Therapeutics guide.You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.
Complementary Tools for Sarepta Stock analysis
When running Sarepta Therapeutics' price analysis, check to measure Sarepta Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sarepta Therapeutics is operating at the current time. Most of Sarepta Therapeutics' value examination focuses on studying past and present price action to predict the probability of Sarepta Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sarepta Therapeutics' price. Additionally, you may evaluate how the addition of Sarepta Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency |
Is Sarepta Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sarepta Therapeutics. If investors know Sarepta will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sarepta Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (5.79) | Revenue Per Share 13.456 | Quarterly Revenue Growth 0.535 | Return On Assets (0.05) | Return On Equity (0.86) |
The market value of Sarepta Therapeutics is measured differently than its book value, which is the value of Sarepta that is recorded on the company's balance sheet. Investors also form their own opinion of Sarepta Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Sarepta Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sarepta Therapeutics' market value can be influenced by many factors that don't directly affect Sarepta Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sarepta Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Sarepta Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sarepta Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.